OverviewSuggest Edit

EnteroBiotix is a clinical stage microbiome therapeutics company. It leverages the gut microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections and gastrointestinal conditions. The company uses its MHRA-licensed platform capabilities and patent-pending technology to advance three core product portfolios that build on the science of the medical treatment known as fecal microbiota transplantation.

HQForesterhill, GB

Latest Updates

Employees (est.) (Sept 2021)22(+5%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at EnteroBiotix

Michael J. Butler

Michael J. Butler

Chief Executive Officer
Gregor Russell

Gregor Russell

James R. McIlroy

James R. McIlroy

Chief Technical Officer
Show more

EnteroBiotix Office Locations

EnteroBiotix has an office in Foresterhill
Foresterhill, GB (HQ)
Foresterhill Rd
Show all (1)

EnteroBiotix Financials and Metrics

Summary Metrics

Founding Date


EnteroBiotix total Funding

$3.2 m

EnteroBiotix latest funding size

$2.53 m

Time since last funding

2 years ago

EnteroBiotix investors

EnteroBiotix's latest funding round in May 2019 was reported to be $2.5 m. In total, EnteroBiotix has raised $3.2 m
Show all financial metrics

EnteroBiotix Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

EnteroBiotix Online and Social Media Presence

Embed Graph

EnteroBiotix News and Updates

EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

GLASGOW, Scotland, Sept. 7, 2021 /PRNewswire/ -- EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK...

EnteroBiotix Blogs

Response to FMT safety alert issued by the FDA

EnteroBiotix is aware of a safety alert issued by the FDA on 13/06/2019 regarding two patients who acquired Extended Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli infections after receiving faecal microbiota transplantation (FMT). In the alert, the FDA state that the faecal microbiota tr…

EnteroBiotix secure key additional MHRA license and announces regulatory milestones

MHRA MIA (IMP) license enables international clinical trial manufacture and distribution  EnteroBiotix meets with European Medicines Agency Innovation Task Force (ITF) in Amsterdam Founding member of Intestinal Microbiome Medicine European Task Group (IMM-ETG) Aberdeen, Scotland and Cambridge, MA, 1…

EnteroBiotix secures £2m seed extension investment and opens new office in Boston, USA

ABERDEEN, Scotland & CAMBRIDGE, Mass. EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, has closed an oversubscribed seed extension investment and is set for international expansion following the opening of a new office in Boston, US. Ent…

EnteroBiotix Frequently Asked Questions

  • When was EnteroBiotix founded?

    EnteroBiotix was founded in 2017.

  • Who are EnteroBiotix key executives?

    EnteroBiotix's key executives are Michael J. Butler, Gregor Russell and James R. McIlroy.

  • How many employees does EnteroBiotix have?

    EnteroBiotix has 26 employees.

  • Who are EnteroBiotix competitors?

    Competitors of EnteroBiotix include Cybele Microbiome, NeurAxon Pharma and ZeCardio Therapeutics.

  • Where is EnteroBiotix headquarters?

    EnteroBiotix headquarters is located at Foresterhill Rd, Foresterhill.

  • Where are EnteroBiotix offices?

    EnteroBiotix has an office in Foresterhill.

  • How many offices does EnteroBiotix have?

    EnteroBiotix has 1 office.